292 related articles for article (PubMed ID: 10750472)
1. Cost analysis of a provincial drug program to guide the treatment of upper gastrointestinal disorders.
Bursey F; Crowley M; Janes C; Turner CJ
CMAJ; 2000 Mar; 162(6):817-23. PubMed ID: 10750472
[TBL] [Abstract][Full Text] [Related]
2. The effect of a Helicobacter pylori treatment strategy on health care expenditures in patients with peptic ulcer disease and dyspepsia.
Kearney DJ; Liu CF; Crump C; Brousal A
Am J Gastroenterol; 2003 Sep; 98(9):1952-62. PubMed ID: 14499771
[TBL] [Abstract][Full Text] [Related]
3. Duodenal ulcer and gastroesophageal reflux disease today: long-term therapy--a sideways glance.
Bardhan KD
Yale J Biol Med; 1996; 69(3):211-24. PubMed ID: 9165690
[TBL] [Abstract][Full Text] [Related]
4. A practice-based approach for converting from proton pump inhibitors to less costly therapy.
Lucas LM; Gerrity MS; Anderson T
Eff Clin Pract; 2001; 4(6):263-70. PubMed ID: 11769299
[TBL] [Abstract][Full Text] [Related]
5. Proton pump inhibitors and hospital discharge rates for gastrointestinal events in Italy: a national ecological study.
Russo P; Brutti C
Clin Ther; 2007 Apr; 29(4):751-8. PubMed ID: 17617299
[TBL] [Abstract][Full Text] [Related]
6. [Dyspepsia and heartburn in primary care: a rational and economic approach].
Labenz J
MMW Fortschr Med; 2009 Aug; 151(34-35):47-8. PubMed ID: 19771792
[No Abstract] [Full Text] [Related]
7. Helicobacter pylori and non-malignant diseases.
Rokkas T; Simsek I; Ladas S
Helicobacter; 2007 Oct; 12 Suppl 1():20-2. PubMed ID: 17727456
[TBL] [Abstract][Full Text] [Related]
8. [Helicobacter pylori eradication in ulcer patients. Quality of life improves, costs decline].
MMW Fortschr Med; 2003 Aug; 145(33-34):55. PubMed ID: 14526577
[No Abstract] [Full Text] [Related]
9. Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children.
Canani RB; Cirillo P; Roggero P; Romano C; Malamisura B; Terrin G; Passariello A; Manguso F; Morelli L; Guarino A;
Pediatrics; 2006 May; 117(5):e817-20. PubMed ID: 16651285
[TBL] [Abstract][Full Text] [Related]
10. Review article: the pharmacodynamics and pharmacokinetics of proton pump inhibitors--overview and clinical implications.
Robinson M
Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 6():1-10. PubMed ID: 15496213
[TBL] [Abstract][Full Text] [Related]
11. Chronic acid-related disorders are common and underinvestigated.
Majumdar SR; Soumerai SB; Farraye FA; Lee M; Kemp JA; Henning JM; Schrammel P; LeCates RF; Ross-Degnan D
Am J Gastroenterol; 2003 Nov; 98(11):2409-14. PubMed ID: 14638341
[TBL] [Abstract][Full Text] [Related]
12. [Long-term course of reflux symptoms following Helicobacter pylori eradication].
Peitz U; Raps S; Plein K; Leodolter A; Hotz Dagger J; Malfertheiner P
Dtsch Med Wochenschr; 2004 Mar; 129(13):671-5. PubMed ID: 15026962
[TBL] [Abstract][Full Text] [Related]
13. Pretreatment antimicrobial susceptibility testing is cost saving in the eradication of Helicobacter pylori.
Romano M; Marmo R; Cuomo A; De Simone T; Mucherino C; Iovene MR; Montella F; Tufano MA; Del Vecchio Blanco C; Nardone G
Clin Gastroenterol Hepatol; 2003 Jul; 1(4):273-8. PubMed ID: 15017668
[TBL] [Abstract][Full Text] [Related]
14. Prescribing proton pump inhibitors for initial treatment of acid-related gastrointestinal diseases in a managed care population.
Chan J; Hui RL; Szpakowski JL
Am J Manag Care; 2004 Jul; 10(7 Pt 1):433-41. PubMed ID: 15298365
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological and pharmacodynamic essentials of H(2)-receptor antagonists and proton pump inhibitors for the practising physician.
Huang JQ; Hunt RH
Best Pract Res Clin Gastroenterol; 2001 Jun; 15(3):355-70. PubMed ID: 11403532
[TBL] [Abstract][Full Text] [Related]
16. Proton pump inhibitors. Compliance with a mandated step-up program.
Mamdani MM; Tu K; Jaakkimainen L; Bica A; Hux J
Can Fam Physician; 2001 Mar; 47():531-5. PubMed ID: 11281086
[TBL] [Abstract][Full Text] [Related]
17. Gastroprotective drugs in Australia: utilization patterns between 1997 and 2006 in relation to NSAID prescribing.
Barozzi N; Tett SE
Clin Ther; 2009 Apr; 31(4):849-61. PubMed ID: 19446158
[TBL] [Abstract][Full Text] [Related]
18. Helicobacter pylori eradication in peptic dyspepsia.
Lule GN
East Afr Med J; 2005 Dec; 82(12):601-2. PubMed ID: 16619702
[No Abstract] [Full Text] [Related]
19. Comparison of amoxicillin-metronidazole plus famotidine or lansoprazole for amoxicillin-clarithromycin-proton pump inhibitor treatment failures for Helicobacter pylori infection.
Murakami K; Okimoto T; Kodama M; Sato R; Miyajima H; Ono M; Inoue K; Watanabe K; Otsu S; Fujioka T
Helicobacter; 2006 Oct; 11(5):436-40. PubMed ID: 16961805
[TBL] [Abstract][Full Text] [Related]
20. Eradication rates of helicobacter pylori infection with second-line treatment: non-ulcer dyspepsia compared to peptic ulcer disease.
Chung SJ; Lee DH; Kim N; Jung SH; Kim JW; Hwang JH; Park YS; Lee KH; Jung HC; Song IS
Hepatogastroenterology; 2007 Jun; 54(76):1293-6. PubMed ID: 17629092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
